Safety and Efficacy of Dupilumab in an Atopic Adolescent With Primary Immune Deficiency

Dermatitis. 2021 Oct 1;32(1S):e91-e92. doi: 10.1097/DER.0000000000000712.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Dermatitis, Atopic / complications
  • Dermatitis, Atopic / drug therapy*
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Primary Immunodeficiency Diseases / diagnosis*
  • Primary Immunodeficiency Diseases / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • dupilumab